JPWO2022034524A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022034524A5 JPWO2022034524A5 JP2023509679A JP2023509679A JPWO2022034524A5 JP WO2022034524 A5 JPWO2022034524 A5 JP WO2022034524A5 JP 2023509679 A JP2023509679 A JP 2023509679A JP 2023509679 A JP2023509679 A JP 2023509679A JP WO2022034524 A5 JPWO2022034524 A5 JP WO2022034524A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- ilt2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2020/050889 WO2021028921A1 (en) | 2019-08-12 | 2020-08-12 | Antibodies against ilt2 and use thereof |
| ILPCT/IL2020/050889 | 2020-08-12 | ||
| US202163145604P | 2021-02-04 | 2021-02-04 | |
| US63/145,604 | 2021-02-04 | ||
| US202163149371P | 2021-02-15 | 2021-02-15 | |
| US63/149,371 | 2021-02-15 | ||
| PCT/IB2021/057414 WO2022034524A2 (en) | 2020-08-12 | 2021-08-11 | Antibodies against ilt2 and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537396A JP2023537396A (ja) | 2023-08-31 |
| JP2023537396A5 JP2023537396A5 (https=) | 2024-08-20 |
| JPWO2022034524A5 true JPWO2022034524A5 (https=) | 2024-08-20 |
Family
ID=80223922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509679A Pending JP2023537396A (ja) | 2020-08-12 | 2021-08-11 | Ｉｌｔ２に対する抗体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12071479B2 (https=) |
| EP (1) | EP4196227A2 (https=) |
| JP (1) | JP2023537396A (https=) |
| KR (1) | KR20230058074A (https=) |
| CN (1) | CN116096756A (https=) |
| AU (1) | AU2021325430A1 (https=) |
| BR (1) | BR112023002301A2 (https=) |
| CA (1) | CA3190634A1 (https=) |
| CO (1) | CO2023002375A2 (https=) |
| IL (1) | IL300588A (https=) |
| MX (1) | MX2023001776A (https=) |
| TW (1) | TW202221035A (https=) |
| WO (1) | WO2022034524A2 (https=) |
| ZA (1) | ZA202302392B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022001841A (es) | 2019-08-12 | 2022-08-17 | Biond Biologics Ltd | Anticuerpos contra ilt2 y uso de los mismos. |
| US20250197491A1 (en) * | 2022-03-11 | 2025-06-19 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
| CN116082500B (zh) * | 2022-12-09 | 2023-08-22 | 珠海重链生物科技有限公司 | 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用 |
| WO2024207855A1 (zh) * | 2023-04-04 | 2024-10-10 | 成都优洛生物科技有限公司 | 抗lilrb1抗体或其抗原结合片段、制备方法和用途 |
| US20250019441A1 (en) | 2023-07-11 | 2025-01-16 | Biond Biologics Ltd. | Treatment of cancer with anti-ilt2 antibodies |
| TW202525855A (zh) * | 2023-08-31 | 2025-07-01 | 美商艾克塞里克斯公司 | Ｉｌｔ２結合劑及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| US7803376B2 (en) | 2003-07-24 | 2010-09-28 | Innate Pharma S.A. | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| EP3209769B1 (en) | 2014-10-24 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| CA3012055A1 (en) | 2016-01-21 | 2017-07-27 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
| EP3740224A4 (en) * | 2018-01-18 | 2022-05-04 | Adanate, Inc. | ANTI-LILRB ANTIBODIES AND THEIR USES |
| WO2020006347A1 (en) * | 2018-06-29 | 2020-01-02 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
| US20210301020A1 (en) | 2018-07-24 | 2021-09-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| EP3902829A2 (en) * | 2018-12-26 | 2021-11-03 | Innate Pharma | Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies |
| MX2022001841A (es) | 2019-08-12 | 2022-08-17 | Biond Biologics Ltd | Anticuerpos contra ilt2 y uso de los mismos. |
| EP4045535A1 (en) | 2019-10-14 | 2022-08-24 | Innate Pharma | Treatment of cancer with ilt-2 inhibitors |
| WO2021133036A1 (ko) | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항-lilrb1 항체 및 그의 용도 |
| AU2021265801B2 (en) | 2020-05-01 | 2026-04-02 | Ngm Biopharmaceuticals, Inc. | ILT-binding agents and methods of use thereof |
-
2021
- 2021-08-11 KR KR1020237008527A patent/KR20230058074A/ko active Pending
- 2021-08-11 IL IL300588A patent/IL300588A/en unknown
- 2021-08-11 AU AU2021325430A patent/AU2021325430A1/en active Pending
- 2021-08-11 US US17/399,971 patent/US12071479B2/en active Active
- 2021-08-11 JP JP2023509679A patent/JP2023537396A/ja active Pending
- 2021-08-11 MX MX2023001776A patent/MX2023001776A/es unknown
- 2021-08-11 EP EP21763407.0A patent/EP4196227A2/en active Pending
- 2021-08-11 WO PCT/IB2021/057414 patent/WO2022034524A2/en not_active Ceased
- 2021-08-11 CN CN202180056995.1A patent/CN116096756A/zh active Pending
- 2021-08-11 CA CA3190634A patent/CA3190634A1/en active Pending
- 2021-08-11 BR BR112023002301A patent/BR112023002301A2/pt unknown
- 2021-08-11 TW TW110129661A patent/TW202221035A/zh unknown
-
2023
- 2023-02-23 ZA ZA2023/02392A patent/ZA202302392B/en unknown
- 2023-02-28 CO CONC2023/0002375A patent/CO2023002375A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| JP7320498B2 (ja) | Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 | |
| US10047163B2 (en) | Multispecific constructs | |
| US20220380468A1 (en) | Modulation of immune response using btla agonist antibodies | |
| JP2020520665A5 (https=) | ||
| JP2017530722A (ja) | 抗ｐｄ−１抗体 | |
| JP2018533371A5 (https=) | ||
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP2021502360A (ja) | 二重特異的融合ポリペプチド及びその使用方法 | |
| JP2020534017A5 (https=) | ||
| JP2022517461A (ja) | Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 | |
| JP2025118688A5 (https=) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| US20210230262A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| JP7676594B2 (ja) | 抗ｃｄ９８抗体及びその応用 | |
| JPWO2021222544A5 (https=) | ||
| JPWO2022034524A5 (https=) | ||
| JP2025513588A (ja) | 抗ｉｌｔ３抗体およびその使用 | |
| JP2022526856A5 (https=) | ||
| JPWO2019204462A5 (https=) | ||
| US20220025034A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| JPWO2020210768A5 (https=) | ||
| TW202600602A (zh) | ４－１ｂｂ配體細胞外域的突變蛋白、包含其的融合蛋白及其用途 |